Core Viewpoint - The recent acquisition of 70% stake in Gao Mai Health by Yimai Yangguang (02522) is seen as a strategic move to enhance its position in the nuclear medicine sector, indicating a potential for value re-evaluation in the company and the industry as a whole [1][3][10]. Group 1: Company Developments - Yimai Yangguang has seen a significant increase in trading activity, with an average daily trading volume of approximately HKD 280 million over the past 12 trading days, indicating strong market interest [1]. - The company's management collectively purchased 208,000 H-shares, signaling confidence in the company's future and suggesting that the stock is undervalued [1]. - Following the acquisition announcement, the company's stock price surged over 10%, reflecting market recognition of the potential value creation from the deal [12]. Group 2: Strategic Positioning - The acquisition of Gao Mai Health completes a critical piece of Yimai Yangguang's nuclear medicine strategy, creating a full industry chain that integrates imaging services, nuclear medicine, and AI [3][4]. - The company aims to establish a "drug-service-data-AI" integrated business model, enhancing its market leadership and operational capabilities [4][5]. - The "One County, One Nuclear Medicine" policy is expected to accelerate the company's growth, as it leverages its unique resources and data assets to drive performance [1][4]. Group 3: Industry Trends - The third-party medical imaging industry is undergoing a significant transformation, with mergers and acquisitions expected to increase from HKD 2.8 billion in 2021 to HKD 9.2 billion by 2024, reflecting a compound annual growth rate of 48% [8]. - The industry is shifting from being a "supporting role" in healthcare to becoming a "core node" in the health industry, driven by policy, capital, and technological advancements [8][9]. - Yimai Yangguang's strategic positioning is seen as a benchmark for value re-evaluation in the third-party medical imaging sector, as it integrates technology, data, and business models [10][12].